<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cardiovasc Med</journal-id><journal-id journal-id-type="iso-abbrev">Front Cardiovasc Med</journal-id><journal-id journal-id-type="publisher-id">Front. Cardiovasc. Med.</journal-id><journal-title-group><journal-title>Frontiers in Cardiovascular Medicine</journal-title></journal-title-group><issn pub-type="epub">2297-055X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40401224</article-id><article-id pub-id-type="pmc">PMC12092434</article-id><article-id pub-id-type="doi">10.3389/fcvm.2025.1560743</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cardiovascular Medicine</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Intravascular lithotripsy vs. rotational atherectomy on coronary microcirculation: a retrospective multicenter propensity-matched multicenter study</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhang</surname><given-names>Xi</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="an1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/validation/"/><role content-type="https://credit.niso.org/contributor-roles/visualization/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Wang</surname><given-names>Peijian</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="an1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Li</surname><given-names>Chenguang</given-names></name><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="an1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1643605/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhao</surname><given-names>Tao</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="an1" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Jiaji</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Bin</given-names></name><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/2952762/overview"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Jin</surname><given-names>Qing</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/software/"/></contrib><contrib contrib-type="author"><name><surname>Gan</surname><given-names>Pin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jilei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Xue</surname><given-names>Qiang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/2717463/overview"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/resources/"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><institution>Department of Cardiology, Yan'an Hospital of Kunming City, Yan'an Hospital Affiliated to Kunming Medical University</institution>, <addr-line>Kunming</addr-line>, <country>China</country></aff><aff id="aff2"><label><sup>2</sup></label><institution>Kunming Cardiovascular Interventional Imaging Institute, Yan'an Hospital of Kunming City, Yan'an Hospital Affiliated to Kunming Medical University</institution>, <addr-line>Kunming</addr-line>, <country>China</country></aff><aff id="aff3"><label><sup>3</sup></label><institution>Yunnan Key Laboratory of Cardiovascular Disease, Yan'an Hospital of Kunming City, Yan'an Hospital Affiliated to Kunming Medical University</institution>, <addr-line>Kunming</addr-line>, <country>China</country></aff><aff id="aff4"><label><sup>4</sup></label><institution>Department of Cardiology, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country></aff><aff id="aff5"><label><sup>5</sup></label><institution>Department of Cardiology, Zhongshan Hospital of Fudan University, Shanghai Institute of Cardiovascular Diseases</institution>, <addr-line>Shanghai</addr-line>, <country>China</country></aff><aff id="aff6"><label><sup>6</sup></label><institution>Department of Cardiology, The Fifth Affiliated Hospital of Kunming Medical University, Gejiu People&#x02019;s Hospital</institution>, <addr-line>Gejiu, Yunnan</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Georges Leftheriotis, Universit&#x000e9; C&#x000f4;te d'Azur, France</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Ankush Gupta, Army Institute of Cardiothoracic Sciences (AICTS), India</p><p>Michel Zeitouni, H&#x000f4;pitaux Universitaires Piti&#x000e9; Salp&#x000ea;tri&#x000e8;re, France</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Qiang Xue <email>xueqiang3513@126.com</email></corresp><fn fn-type="equal" id="an1"><label>
<sup>&#x02020;</sup>
</label><p>These authors have contributed equally to this work and share first authorship</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>12</volume><elocation-id>1560743</elocation-id><history><date date-type="received"><day>14</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Zhang, Wang, Li, Zhao, He, Liu, Jin, Gan, Zhang and Xue.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Zhang, Wang, Li, Zhao, He, Liu, Jin, Gan, Zhang and Xue</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Background</title><p>Coronary microvascular dysfunction (CMD) predicts poor prognosis in patients with coronary artery disease (CAD). However, the impact of intravascular lithotripsy (IVL) on CMD remains unclear, and no studies have directly compared IVL and rotational atherectomy (RA) in the context of CMD.</p></sec><sec><title>Objective</title><p>This study aimed to evaluate CMD, as indicated by angiographic microvascular resistance (AMR), in patients undergoing IVL- or RA-assisted PCI for heavily calcified coronary lesions.</p></sec><sec><title>Methods</title><p>This multicenter retrospective cohort study enrolled patients underwent either RA- or IVL-assisted percutaneous coronary intervention (PCI) at three centers. Propensity score matching (1:2) was performed to control for potential bias. The primary outcomes included the post-PCI AMR values and CMD incidence. The secondary outcomes included peri-procedural adverse events (PPAEs).</p></sec><sec><title>Results</title><p>A total of 377 patients were registered, and 210 propensity-matched patients (140 RA vs. 70 IVL) were analyzed. Pre-PCI AMR was similar between the groups (RA 1.24&#x02009;&#x000b1;&#x02009;0.53 vs. IVL 1.28&#x02009;&#x000b1;&#x02009;0.50, <italic>p</italic>&#x02009;=&#x02009;0.615). Following PCI, AMR was significantly higher in the RA group compared to IVL (2.43&#x02009;&#x000b1;&#x02009;0.35 vs. 2.26&#x02009;&#x000b1;&#x02009;0.50, <italic>p</italic>&#x02009;=&#x02009;0.015), while CMD incidence was comparable (RA 32.9% vs. IVL 27.1%, <italic>p</italic>&#x02009;=&#x02009;0.398). In addition, the PPAEs rates were lower in the IVL group but the difference showed no statistical significance (27.9% vs. 17.1%, <italic>p</italic>&#x02009;=&#x02009;0.088).</p></sec><sec><title>Conclusions</title><p>IVL demonstrates less microvascular dysfunction compared to RA, as indicated by lower post-PCI AMR. These findings suggest that IVL may offer advantages in preserving coronary microvascular function across various clinical scenarios when both techniques are equally available and applicable, but further large-scale prospective studies are needed to verify these results.</p></sec></abstract><kwd-group><kwd>intravascular lithotripsy (IVL)</kwd><kwd>rotational atherectomy (RA)</kwd><kwd>coronary microcirculatory function (CMD)</kwd><kwd>angiographic microvascular resistance (AMR)</kwd><kwd>peri-procedural adverse events (PPAEs)</kwd><kwd>multicenter study</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Kunming Cardiovascular Interventional Imaging Institute</funding-source><award-id award-type="contract" rid="cn001">2023-SW-01</award-id></award-group><award-group><funding-source id="cn002">China Scholarship Council</funding-source><award-id award-type="contract" rid="cn002">202108535042</award-id></award-group><award-group><funding-source id="cn003">Yunnan Provincial Department of Education Science Research Program</funding-source><award-id award-type="contract" rid="cn003">2024J0280</award-id></award-group></funding-group><funding-group><funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by funds from Kunming Cardiovascular Interventional Imaging Institute [grant numbers 2023-SW-01], funds from the China Scholarship Council [grant numbers 202108535042], and funds from the Yunnan Provincial Department of Education Science Research Program [grant numbers 2024J0280]. The funding organization played no role in the design of the study and did not participate in study execution, analysis, or interpretation of the data, or the decision to submit the results for publication.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="2"/><equation-count count="1"/><ref-count count="38"/><page-count count="9"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Atherosclerosis and Vascular Medicine</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>With the aging population and increasing prevalence of diabetes mellitus and chronic kidney disease, calcified coronary artery disease (CAD) has emerged as a significant challenge in interventional cardiology (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>).</p><p>Calcified plaques in coronary arteries obstruct balloon dilatation and effective stent delivery, leading to malposition, stent under expansion, and drug-eluting polymer coat degradation (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). These complications compromise procedural success and result in an elevated risk of ischemic events, which can severely impact long-term prognosis (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>).</p><p>Several treatment modalities have been developed to address this challenge (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Rotational atherectomy (RA) utilizes a rapidly rotating burr to ablate and modify calcified plaques and has demonstrated superior acute luminal gain and more successful stent delivery compared to balloon angioplasty alone (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B5" ref-type="bibr">5</xref>). Calcification debris was reported to cause coronary microvascular dysfunction (CMD). This translates to poorer procedural outcomes and increases the risk of major adverse cardiovascular events (MACE) (<xref rid="B8" ref-type="bibr">8</xref>).</p><p>In contrast, intravascular lithotripsy is a balloon-based device equipped with lithotripsy emitters. IVL induces fractures in intraplaque calcium by emitting sonic waves that are evenly distributed across the balloon surface, thereby facilitating plaque modification (<xref rid="B9" ref-type="bibr">9</xref>&#x02013;<xref rid="B11" ref-type="bibr">11</xref>). Single-arm studies investigating IVL have reported promising results, including the prospective, multicenter DISRUPT CAD phase I, II, and III trials. Furthermore, IVL offers several advantages, such as lower debris generation and vascular intimal injury during the procedure, as well as a low complication rate (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B12" ref-type="bibr">12</xref>). Notably, the calcific lesions treated with IVL were generally less severe and complex than those addressed by RA (<xref rid="B13" ref-type="bibr">13</xref>), which may partially account for the observed differences in microcirculatory outcomes.</p><p>In theory, these advantages minimize damage to the microcirculation. However, the effect of IVL on coronary microcirculation function remains unclear due to the lack of trials comparing IVL to RA in the context of CMD.</p><p>The microcirculatory system can be evaluated using several methods, but noninvasive techniques such as positron emission tomography (PET) and index of microcirculatory resistance (IMR) remain underutilized. Among invasive assessment tools, wire-based IMR and coronary flow reserve (CFR) have seen limited use due to low repeatability and inconvenience despite being considered the most reliable indicators of microcirculatory function (<xref rid="B14" ref-type="bibr">14</xref>&#x02013;<xref rid="B16" ref-type="bibr">16</xref>). Previous research has established that invasive measurements are independently associated with adverse outcomes in various cardiovascular diseases (<xref rid="B17" ref-type="bibr">17</xref>&#x02013;<xref rid="B19" ref-type="bibr">19</xref>). To address these challenges, angiographic microvascular resistance (AMR) has been developed as a calculation method based on computational flow and pressure dynamics, providing a promising alternative to wire-derived IMR. AMR has gained popularity due to its simplicity and consistency with wire-based IMR. Previous studies have demonstrated that AMR is a viable alternative for assessing coronary microcirculatory function (<xref rid="B20" ref-type="bibr">20</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>).</p><p>This study aims to compare the impact of RA or IVL on coronary microcirculatory function indicated by AMR in patients with calcified coronary artery disease treated with PCI. This study is the first to evaluate coronary microcirculatory function in patients undergoing IVL and highlights the first comparison of coronary microcirculatory function between IVL therapy and RA.</p></sec><sec sec-type="methods" id="s2"><label>2</label><title>Methods</title><sec id="s2a"><label>2.1</label><title>Study design and population</title><p>This multicenter and retrospective study included consecutive patients from September 2022 to September 2024 from three centers, namely Yan'an Hospital of Kunming City, Zhongshan Hospital of Fudan University, and The First Affiliated Hospital of Chengdu Medical College, who underwent PCI facilitated either by RA or IVL referring to the guidelines. Severe calcification was defined as either &#x02265;270-degree arc of calcium on intravascular imaging, angiographic evidence of severe calcification blocking device passage, or a non-compliant balloon expand. The exclusion criteria in the clinical settings were as follows: (1) underwent both RA and IVL; (2) unavailability of follow-up data; (3) acute myocardial infarction; (4) left main PCI; (5) in-stent restenosis; (6) stenting of both the main and side branch. The exclusion criteria for angiography were: (1) missing preoperative or postoperative contrast; (2) AMR analysis could not be performed due to the inability to detect vessel borders or poorly filled contrast, excessive overlap of stenotic segments, or severely tortuous lesions in the target vessel. All interventions were performed in accordance with the guidelines outlined in the Declaration of Helsinki. The requirement for informed consent was waived owing to the retrospective nature of the study.</p></sec><sec id="s2b"><label>2.2</label><title>Procedural techniques</title><p>Coronary angiography was conducted according to conventional and local standards. An IVL catheter (Shockwave Medical, Santa Clara, CA, USA) was equipped with an integrated balloon that housed multiple lithotripsy emitters generating sonic pressure waves. Following the standard procedure, the balloon catheter was sized 1:1 to the reference artery and advanced over a coronary guidewire to the target lesion using a mono-rail technique. The balloon was inflated to a low pressure [4 atmospheres (atm)] to ensure vessel wall contact while minimizing the risk of barotrauma. Up to 10 impulses were delivered (1 pulse per second for 10&#x02005;s, for a total of 80 pulses). Subsequently, the balloon was further inflated to the nominal pressure (6 atm) and then deflated to restore blood flow. In cases with multiple lesions, each lesion was treated with a minimum of 20 pulses.</p><p>RA was performed using the Rotablator (Boston Scientific, Marlborough, MA, USA) as per standard of care. Intraoperative irrigation was performed with heparinized saline to minimize the incidence of decreased blood flow.</p><p>Pre- and post-dilatation were permitted at the discretion of the operator. All patients received dual antiplatelet therapy prior to PCI, consisting of aspirin in combination with either clopidogrel or ticagrelor, as well as intraprocedural heparin administration, in accordance with current clinical guidelines (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B24" ref-type="bibr">24</xref>). Peri-procedural adverse events (PPAEs), including coronary slow flow or no flow after the procedure, coronary dissection, burr entrapment, side branch occlusion, peripheral vascular complications, contrast-induced nephropathy, myocardial injury, procedure-related myocardial infarction (MI), and in-hospital death, were recorded. Coronary slow flow/no flow referred to instant thrombolysis in myocardial infarction (TIMI) flow grade &#x0003c;3 post-procedure, without visible thrombosis, dissection, or spasm. Procedure-related MI was defined as an elevation of cardiac troponin (cTn) levels &#x0003e;5 times the normal upper limit, accompanied by recurrent symptoms with or without new ST-segment changes. Increased cTn values in patients with normal baseline values or a rise in cTn values &#x0003e;20% of the baseline were regarded as myocardial injury (<xref rid="B25" ref-type="bibr">25</xref>).</p></sec><sec id="s2c"><label>2.3</label><title>AMR computation and CMD definition</title><p>AMR was assessed by two independent specialists who were blinded to the patients' clinical characteristics and details regarding prior RA surgeries and clinical outcomes. Discrepancies in evaluation were settled by an independent analysis by a third specialist, and consensus was reached through subsequent discussions.</p><p>The methodology for calculating Murray's law-based quantitative flow ratio (<italic>&#x003bc;</italic>QFR) and AMR has been previously described (<xref rid="F1" ref-type="fig">Figure&#x000a0;1</xref>). Briefly, coronary angiography (CAG) images that met the predefined criteria were imported into AngioPlus software (Pulse Medical Technology). Coronary artery revascularization was conducted in accordance with Murray's law, and &#x003bc;QFR was calculated simultaneously with simulated flow velocities under hyperemic conditions (<xref rid="B26" ref-type="bibr">26</xref>). Distal coronary pressure (Pd) was derived from the pressure drop, and AMR was then calculated as the ratio of Pd to the simulated hyperemic flow velocity (Velocityhyp) (<xref rid="B27" ref-type="bibr">27</xref>).<disp-formula><mml:math id="UDM1" overflow="scroll"><mml:mrow><mml:mi mathvariant="normal">AMR</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Velocityhyp</mml:mi></mml:mrow></mml:mrow></mml:mfrac></mml:mrow><mml:mo>=</mml:mo><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>P</mml:mi><mml:mi>a</mml:mi><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mi>&#x003bc;</mml:mi><mml:mi mathvariant="normal">QFR</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi mathvariant="normal">Velocityhyp</mml:mi></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:mstyle></mml:math></disp-formula>The AMR measurement performed after CAG was defined as pre-AMR, and the measurement after PCI was defined as post-AMR. Patients exhibiting an AMR &#x02265;2.5&#x02005;mmHg-s/cm were categorized as having CMD (<xref rid="B28" ref-type="bibr">28</xref>).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Examples of QFR and AMR analysis. CAG showed a stenosis in the right coronary artery, and QFR was calculated as 0.98, flow velocity was 18.7&#x02005;cm/s, and AMR was calculated as 2.23&#x02005;mmHg&#x000b7; s/cm. RA, rotational atherectomy; QFR, quantitative flow ratio; AMR, angiographic microvascular resistance; CAG, coronary angiography.</p></caption><graphic xlink:href="fcvm-12-1560743-g001" position="float"/></fig></sec><sec id="s2d"><label>2.4</label><title>Study endpoints</title><p>The primary endpoint was the comparison of the AMR value and rate of CMD between patients treated with IVL and RA. The secondary endpoint was the rate of PPAEs.</p></sec><sec id="s2e"><label>2.5</label><title>Statistical analysis</title><p>Continuous variables conforming to a normal distribution were expressed as mean&#x02009;&#x000b1;&#x02009;standard deviation, while non-normally distributed data were expressed as median and interquartile range. Categorical data were presented as counts and proportions (%). Pearson's <italic>&#x003c7;</italic><sup>2</sup> test and Fisher's exact test were performed for the comparison of categorical variables between groups, and the Mann&#x02013;Whitney <italic>U</italic>-test was performed for continuous variables. A <italic>p</italic>-value of &#x02264;0.05 was considered statistically significant.</p><p>Subsequently, propensity matching was performed for patients treated with IVL and patients treated with RA in a 1:2 ratio using the &#x0201c;Nearest Neighbor&#x0201d; method. The variables included in the propensity score were age, sex, smoking, diabetes, treated vessel, number of affected vessels, current dialysis, and left ventricular ejection fraction (LVEF).</p><p>Statistical analysis was carried out using IBM SPSS Statistics Version 26 (IBM, Armonk, New York, NY, USA) and R software version 3.6.3(R Foundation, Vienna, Austria).</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><p>A total of 377 consecutive patients, of whom 114 underwent IVL and 263 RA, between September 2023 and November 2024 were enrolled in this study. The study flowchart is shown in <xref rid="F2" ref-type="fig">Figure&#x000a0;2</xref>. After exclusions, 270 patients were considered for propensity score matching. The final population consisted of 210 patients, of which 70 were treated with IVL (53% male, median 65 years) and 140 patients with RA (58% male, median 66 years).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>Flow chart of enrolled patients.</p></caption><graphic xlink:href="fcvm-12-1560743-g002" position="float"/></fig><sec id="s3a"><label>3.1</label><title>Baseline characteristics</title><p>As shown in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>, patients' clinical baseline characteristics, laboratory findings, and cardiovascular medical therapy among the two groups were similar. Both RA and IVL groups exhibited a high prevalence of comorbidities, including diabetes mellitus (44.3% vs. 38.6%), hypertension (62.1% vs. 67.0%), and current smoker (42.1% vs. 48.6%).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical baseline, angiographic, and procedural characteristics for the study population.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="2" colspan="1">Variable</th><th valign="top" align="center" rowspan="1" colspan="1">All patients</th><th valign="top" align="center" rowspan="1" colspan="1">RA</th><th valign="top" align="center" rowspan="1" colspan="1">IVL</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">(<italic>n</italic>&#x02009;=&#x02009;210)</th><th valign="top" align="center" rowspan="1" colspan="1">(<italic>n</italic>&#x02009;=&#x02009;140)</th><th valign="top" align="center" rowspan="1" colspan="1">(<italic>n</italic>&#x02009;=&#x02009;70)</th><th valign="top" align="center" rowspan="1" colspan="1">value</th></tr></thead><tbody><tr><td valign="top" align="left" colspan="5" rowspan="1">Clinical baseline characteristics</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">65.61&#x02009;&#x000b1;&#x02009;8.59</td><td valign="top" align="center" rowspan="1" colspan="1">65.95&#x02009;&#x000b1;&#x02009;8.77</td><td valign="top" align="center" rowspan="1" colspan="1">64.94&#x02009;&#x000b1;&#x02009;8.23</td><td valign="top" align="center" rowspan="1" colspan="1">0.800</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Male, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">118 (56.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">81 (57.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">37 (52.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.491</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">24.43&#x02009;&#x000b1;&#x02009;3.04</td><td valign="top" align="center" rowspan="1" colspan="1">24.63&#x02009;&#x000b1;&#x02009;2.79</td><td valign="top" align="center" rowspan="1" colspan="1">24.02&#x02009;&#x000b1;&#x02009;3.48</td><td valign="top" align="center" rowspan="1" colspan="1">0.202</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hypertension, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">134 (63.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">87 (62.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">47 (67.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.477</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diabetes mellitus, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">89 (42.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">62 (44.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">27 (38.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.430</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dyslipidemia, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">108 (51.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">69 (49.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">39 (55.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.380</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TIA, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (9.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (8.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (10.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.734</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CKD, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">8 (3.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (3.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (4.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.799</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Current smoker, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">93 (44.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">59 (42.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">34 (48.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.377</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Previous MI, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">31 (14.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (13.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (17.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.492</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Prior PCI, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">143 (68.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">92 (65.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (72.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.295</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">LVEF, <italic>n</italic> (%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;50%</td><td valign="top" align="center" rowspan="1" colspan="1">158 (75.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">104 (74.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">54 (77.1%)</td><td valign="top" align="center" rowspan="3" colspan="1">0.902</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">35&#x02013;50%</td><td valign="top" align="center" rowspan="1" colspan="1">29 (13.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">20 (14.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (12.9%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;35%</td><td valign="top" align="center" rowspan="1" colspan="1">23 (11.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">16 (11.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (10.0%)</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">Laboratory findings</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HbA1c (%)</td><td valign="top" align="center" rowspan="1" colspan="1">6.01&#x02009;&#x000b1;&#x02009;0.94</td><td valign="top" align="center" rowspan="1" colspan="1">6.04&#x02009;&#x000b1;&#x02009;1.01</td><td valign="top" align="center" rowspan="1" colspan="1">5.97&#x02009;&#x000b1;&#x02009;0.81</td><td valign="top" align="center" rowspan="1" colspan="1">0.627</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LDL (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">2.18&#x02009;&#x000b1;&#x02009;0.75</td><td valign="top" align="center" rowspan="1" colspan="1">2.17&#x02009;&#x000b1;&#x02009;0.84</td><td valign="top" align="center" rowspan="1" colspan="1">2.20&#x02009;&#x000b1;&#x02009;0.53</td><td valign="top" align="center" rowspan="1" colspan="1">0.771</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">HDL (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">1.06&#x02009;&#x000b1;&#x02009;0.27</td><td valign="top" align="center" rowspan="1" colspan="1">1.06&#x02009;&#x000b1;&#x02009;0.29</td><td valign="top" align="center" rowspan="1" colspan="1">1.05&#x02009;&#x000b1;&#x02009;0.23</td><td valign="top" align="center" rowspan="1" colspan="1">0.720</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">GC (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">2.28&#x02009;&#x000b1;&#x02009;2.26</td><td valign="top" align="center" rowspan="1" colspan="1">2.21&#x02009;&#x000b1;&#x02009;2.25</td><td valign="top" align="center" rowspan="1" colspan="1">2.41&#x02009;&#x000b1;&#x02009;2.30</td><td valign="top" align="center" rowspan="1" colspan="1">0.548</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TC (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">3.75&#x02009;&#x000b1;&#x02009;0.98</td><td valign="top" align="center" rowspan="1" colspan="1">3.80&#x02009;&#x000b1;&#x02009;0.96</td><td valign="top" align="center" rowspan="1" colspan="1">3.64&#x02009;&#x000b1;&#x02009;1.03</td><td valign="top" align="center" rowspan="1" colspan="1">0.268</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cr (&#x003bc;mol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">83.92&#x02009;&#x000b1;&#x02009;70.47</td><td valign="top" align="center" rowspan="1" colspan="1">82.81&#x02009;&#x000b1;&#x02009;72.35</td><td valign="top" align="center" rowspan="1" colspan="1">86.14&#x02009;&#x000b1;&#x02009;67.00</td><td valign="top" align="center" rowspan="1" colspan="1">0.748</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">Cardiovascular medical therapy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Aspirin and its analogs, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">210 (100.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">140 (100.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">70 (100.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">P2Y12 receptor antagonist, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">210 (100.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">140 (100.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">70 (100.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Statin, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">203 (96.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">136 (97.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">67 (95.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.892</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">ACEI/ARB/ARNI, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">161 (76.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">111 (79.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">50 (71.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.204</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Beta blocker, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">157 (74.8%)</td><td valign="top" align="center" rowspan="1" colspan="1">108 (77.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">49 (70.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.261</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CCB, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">129(61.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">83(59.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">46(65.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.367</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1"><p>Values are mean&#x02009;&#x000b1;&#x02009;standard deviation, median (interquartile range) or <italic>n</italic> (%); RA, rotational atherectomy&#x0037e; IVL, intravascular lithotripsy; BMI, body mass index; MI, myocardial infarction&#x0037e; PCI, percutaneous coronary intervention&#x0037e; CKD, chronic kidney disease; HbA1c, Hemoglobin A1c; LVEF, left ventricular ejection fraction; LDL, low-density lipoprotein; TC, total cholesterol; Cr, creatinine; ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; CCB, calcium channel blocker.</p></fn><fn id="table-fn2"><label>*</label><p><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></fn></table-wrap-foot></table-wrap><p>Angiographic and procedural details are listed in <xref rid="T2" ref-type="table">Table&#x000a0;2</xref>. RA patients had a higher rate of stenosis in the target vascular region (88.6% vs. 85.0%) and post-dilatation (90.0% vs. 72.9%). In contrast, RA was associated with shorter stent length (33.57&#x02009;&#x000b1;&#x02009;18.00 vs. 44.57&#x02009;&#x000b1;&#x02009;15.49, <italic>p</italic>&#x02009;=&#x02009;0.001) and lower frequency of lesions &#x02265;20&#x02005;mm (78.6% vs. 95.7%, <italic>p</italic>&#x02009;=&#x02009;0.011).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Angiographic and procedural characteristics for the propensity-matched population.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="2" colspan="1">Variable</th><th valign="top" align="center" rowspan="1" colspan="1">All patients</th><th valign="top" align="center" rowspan="1" colspan="1">RA</th><th valign="top" align="center" rowspan="1" colspan="1">IVL</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">(<italic>n</italic>&#x02009;=&#x02009;210)</th><th valign="top" align="center" rowspan="1" colspan="1">(<italic>n</italic>&#x02009;=&#x02009;140)</th><th valign="top" align="center" rowspan="1" colspan="1">(<italic>n</italic>&#x02009;=&#x02009;70)</th><th valign="top" align="center" rowspan="1" colspan="1">value</th></tr></thead><tbody><tr><td valign="top" align="left" colspan="5" rowspan="1">Coronary physiological parameters</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">pre-QFR</td><td valign="top" align="center" rowspan="1" colspan="1">0.57&#x02009;&#x000b1;&#x02009;0.18</td><td valign="top" align="center" rowspan="1" colspan="1">0.57&#x02009;&#x000b1;&#x02009;0.17</td><td valign="top" align="center" rowspan="1" colspan="1">0.56&#x02009;&#x000b1;&#x02009;0.18</td><td valign="top" align="center" rowspan="1" colspan="1">0.856</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">pre-Velocityhyp (cm/s)</td><td valign="top" align="center" rowspan="1" colspan="1">15.03&#x02009;&#x000b1;&#x02009;4.75</td><td valign="top" align="center" rowspan="1" colspan="1">15.15&#x02009;&#x000b1;&#x02009;4.85</td><td valign="top" align="center" rowspan="1" colspan="1">14.80&#x02009;&#x000b1;&#x02009;4.59</td><td valign="top" align="center" rowspan="1" colspan="1">0.622</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">pre-AMR (mmHg&#x000b7;s/cm)</td><td valign="top" align="center" rowspan="1" colspan="1">1.26&#x02009;&#x000b1;&#x02009;0.52</td><td valign="top" align="center" rowspan="1" colspan="1">1.24&#x02009;&#x000b1;&#x02009;0.53</td><td valign="top" align="center" rowspan="1" colspan="1">1.28&#x02009;&#x000b1;&#x02009;0.50</td><td valign="top" align="center" rowspan="1" colspan="1">0.615</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">post-AMR (mmHg&#x000b7;s/cm)</td><td valign="top" align="center" rowspan="1" colspan="1">2.37&#x02009;&#x000b1;&#x02009;0.41</td><td valign="top" align="center" rowspan="1" colspan="1">2.43&#x02009;&#x000b1;&#x02009;0.35</td><td valign="top" align="center" rowspan="1" colspan="1">2.26&#x02009;&#x000b1;&#x02009;0.50</td><td valign="top" align="center" rowspan="1" colspan="1">0.015<xref rid="table-fn4" ref-type="table-fn">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x025b3;AMR (mmHg&#x000b7;s/cm)</td><td valign="top" align="center" rowspan="1" colspan="1">1.11&#x02009;&#x000b1;&#x02009;0.60</td><td valign="top" align="center" rowspan="1" colspan="1">1.19&#x02009;&#x000b1;&#x02009;0.61</td><td valign="top" align="center" rowspan="1" colspan="1">0.98&#x02009;&#x000b1;&#x02009;0.61</td><td valign="top" align="center" rowspan="1" colspan="1">0.024<xref rid="table-fn4" ref-type="table-fn">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">CMD, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">65 (31.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">46 (32.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">19 (27.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.398</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">Angiographic and procedural characteristics</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">Target vessel, <italic>n</italic> (%)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LAD</td><td valign="top" align="center" rowspan="1" colspan="1">159 (75.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">104 (74.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">55 (78.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.715</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">LCX</td><td valign="top" align="center" rowspan="1" colspan="1">16 (7.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (8.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (5.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.492</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">RCA</td><td valign="top" align="center" rowspan="1" colspan="1">35 (16.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">24 (17.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (15.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.295</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stenosis rate of target vascular area (%)</td><td valign="top" align="center" rowspan="1" colspan="1">87.43&#x02009;&#x000b1;&#x02009;6.71</td><td valign="top" align="center" rowspan="1" colspan="1">88.65&#x02009;&#x000b1;&#x02009;6.59</td><td valign="top" align="center" rowspan="1" colspan="1">84.99&#x02009;&#x000b1;&#x02009;6.30</td><td valign="top" align="center" rowspan="1" colspan="1">0.0001<xref rid="table-fn4" ref-type="table-fn">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Three-vessel coronary disease, n(%)</td><td valign="top" align="center" rowspan="1" colspan="1">104 (49.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">71 (50.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">33 (47.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.626</td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">Max Burr Size</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1.25&#x02005;mm</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">29 (20.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1.50&#x02005;mm</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">87 (62.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">1.75&#x02005;mm</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">19 (13.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">2.00&#x02005;mm</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">5 (3.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IVL Balloon Size (mm)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="top" align="center" rowspan="1" colspan="1">3.02&#x02009;&#x000b1;&#x02009;0.29</td><td valign="top" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Postdilatation, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">177 (84.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">126 (90.0%)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (72.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.001<xref rid="table-fn4" ref-type="table-fn">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Number of stents</td><td valign="top" align="center" rowspan="1" colspan="1">2 (2, 2)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (2, 2)</td><td valign="top" align="center" rowspan="1" colspan="1">2 (2, 2)</td><td valign="top" align="center" rowspan="1" colspan="1">0.117</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stent length (mm)</td><td valign="top" align="center" rowspan="1" colspan="1">37.24&#x02009;&#x000b1;&#x02009;17.93</td><td valign="top" align="center" rowspan="1" colspan="1">33.57&#x02009;&#x000b1;&#x02009;18.00</td><td valign="top" align="center" rowspan="1" colspan="1">44.57&#x02009;&#x000b1;&#x02009;15.49</td><td valign="top" align="center" rowspan="1" colspan="1">0.001<xref rid="table-fn4" ref-type="table-fn">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02265;20&#x02005;mm lesion, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">177 (84.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">110 (62.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">67 (37.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.001<xref rid="table-fn4" ref-type="table-fn">*</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Myocardial injury, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">43 (20.5%)</td><td valign="top" align="center" rowspan="1" colspan="1">34 (24.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (12.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.053</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Procedure related-MI, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">18 (8.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">15 (10.7%)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (4.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.117</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Peri-procedural adverse events, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (24.3%)</td><td valign="top" align="center" rowspan="1" colspan="1">39 (27.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (17.1%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.088</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Instant TIMI flow grade &#x0003c;3, <italic>n</italic> (%)</td><td valign="top" align="center" rowspan="1" colspan="1">13(6.2%)</td><td valign="top" align="center" rowspan="1" colspan="1">11(7.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">2(2.9%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.265</td></tr></tbody></table><table-wrap-foot><fn id="table-fn3"><p>Values are mean&#x02009;&#x000b1;&#x02009;standard deviation, median (interquartile range) or n(%); RA, rotational atherectomy&#x0037e; IVL, intravascular lithotripsy; AMR, angiographic microvascular resistance; MI, myocardial infarction&#x0037e; PCI, percutaneous coronary intervention; Velocityhyp, simulated hyperemic flow velocity; CMD, AMR &#x02265;2.5&#x02005;mmHg- s/cm; &#x025b3;AMR&#x02009;=&#x02009;post-RA AMR&#x02014;pre-RA AMR; LAD, left anterior descending artery&#x0037e; LCX, left circumflex; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.</p></fn><fn id="table-fn4"><label>*</label><p><italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><label>3.2</label><title>AMR, myocardial injury, and peri-procedural adverse events</title><p><xref rid="T2" ref-type="table">Table&#x000a0;2</xref> illustrates the coronary microvascular function in the study population. Coronary microvascular function assessed by AMR was measured in 210 target coronary arteries, with the majority of lesions (75.7%) located in the left anterior descending coronary artery. Prior to intervention, similar AMR values were observed in the IVL and RA groups (1.28&#x02009;&#x000b1;&#x02009;0.50 vs. 1.24&#x02009;&#x000b1;&#x02009;0.53, <italic>p</italic>&#x02009;=&#x02009;0.615), and no patients were diagnosed with CMD. Following PCI, AMR values increased in all patients (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>; <xref rid="F3" ref-type="fig">Figure&#x000a0;3</xref>). However, the RA group showed a significantly greater increase in &#x00394;AMR (1.19&#x02009;&#x000b1;&#x02009;0.61 vs. 0.98&#x02009;&#x000b1;&#x02009;0.61, <italic>p</italic>&#x02009;=&#x02009;0.024) and post-AMR (2.43&#x02009;&#x000b1;&#x02009;0.35 vs. 2.26&#x02009;&#x000b1;&#x02009;0.50, <italic>p</italic>&#x02009;=&#x02009;0.015) (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>; and <xref rid="F4" ref-type="fig">Figure&#x000a0;4</xref>). After adjustment for procedure-related MI, the RA group still demonstrated significantly higher post-procedural AMR (adjusted <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) and <italic>&#x00394;</italic>AMR (adjusted <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) compared to the IVL group.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p>Temporal change of angiographic microvascular resistance (AMR) in the target vessels of the two groups. <bold>(A)</bold>: The AMR significantly increased in RA patients from pre- to post-PCI. <bold>(B)</bold>: The AMR significantly increased in post-PCI IVL patients compared to pre-PCI. AMR, Angiographic microvascular resistance&#x0037e; RA, rotational atherectomy; IVL, intravascular lithotripsy.</p></caption><graphic xlink:href="fcvm-12-1560743-g003" position="float"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Angiographic microvascular resistance (AMR) after rotational atherectomy (RA) and intravascular lithotripsy (IVL). <bold>(A)</bold>: Box plot depicting the distribution of the post-PCI AMR between the two groups. <bold>(B)</bold>: Cumulative frequency distribution curves demonstrating lower AMR after IVL compared to RA. AMR, Angiographic microvascular resistance&#x0037e; RA, rotational atherectomy; IVL, intravascular lithotripsy; PCI percutaneous coronary intervention.</p></caption><graphic xlink:href="fcvm-12-1560743-g004" position="float"/></fig><p>A total of 65 patients (31.0%) developed CMD after procedure. Moreover, the incidence of CMD was comparable between the RA and IVL groups (32.9% vs. 27.1%, <italic>p</italic>&#x02009;=&#x02009;0.398).</p><p>Additionally, IVL patients showed a lower incidence of PPAEs compared to RA patients (17.1% vs. 27.9%, <italic>p</italic>&#x02009;=&#x02009;0.088), as well as fewer myocardial injury (12.9% vs. 24.3%, <italic>p</italic>&#x02009;=&#x02009;0.053), procedure-related MI (4.3% vs. 10.7%, <italic>p</italic>&#x02009;=&#x02009;0.117). A lower rate of TIMI flow&#x02009;&#x0003c;&#x02009;3 was also observed, although this did not reach statistical significance (2.9% vs. 7.9%, <italic>p</italic>&#x02009;=&#x02009;0.265).</p></sec></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>This study employed propensity-score matching to compare the impact of RA and IVL on coronary microcirculation function indicated by AMR. Our main findings are as follows: (1) the AMR value was significantly increased in all patients after PCI; (2) the post-PCI AMR value was significantly higher in patients who underwent RA compared to IVL; (3) the incidence of peri-procedural adverse events was comparable between the IVL and RA groups.</p><p>Interventional cardiologists now have an expanded array of tools to address severe coronary artery calcification, such as cutting balloons and lasers, but RA and IVL are the predominant techniques to treat calcified plaques (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B29" ref-type="bibr">29</xref>). While these interventions effectively relieve anatomic obstruction, the recovery of coronary microvascular dysfunction is crucial for improving patient outcomes.</p><p>In recent years, growing evidence has supported the use of CAG-derived IMR, which strongly correlates with wire-based IMR and has gained widespread adoption due to its simplicity (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B30" ref-type="bibr">30</xref>). Notably, AMR, which does not require pressure guidewires or vasodilator drugs, has shown a robust correlation (<italic>r</italic>&#x02009;=&#x02009;0.83, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and diagnostic performance (AUC 0.94; 95% CI: 0.91&#x02013;0.97) when compared to wire-based IMR, using a single angiographic view (<xref rid="B28" ref-type="bibr">28</xref>). Previous studies have shown AMR's strong diagnostic ability in assessing CMD (AUC 87.2 95% CI: 83.0&#x02013;91.3), demonstrating significant, independent associations with adverse events such as MACE and heart failure-related rehospitalizations (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B20" ref-type="bibr">20</xref>&#x02013;<xref rid="B22" ref-type="bibr">22</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B31" ref-type="bibr">31</xref>).</p><p>In our study, AMR values reflecting microcirculation dysfunction were significantly enhanced following PCI in all patients. Furthermore, recent studies have reported the effectiveness and safety of AMR as a tool for optimizing PCI outcomes (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B32" ref-type="bibr">32</xref>). Our results indicate that among patients with RA, the degree of CMD post-PCI was significantly higher than those treated with IVL.</p><p>Mechanistically, IVL distributes energy circumferentially, causing calcium fractures in multiple planes (<xref rid="B30" ref-type="bibr">30</xref>), which confers additional advantages such as reduced vascular intimal injury, preservation of vessel wall fibroelastic integrity, and a lower complication rate. Therefore, IVL induces lower microvascular damage compared to RA. On the other hand, RA pulverizes calcified lesions into fine particles that erode plaques (<xref rid="B29" ref-type="bibr">29</xref>). The size of these particles is smaller than that of red blood cells and can be efficiently cleared by the reticuloendothelial system (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>). Continuous active hypertension protection and a flushing solution (composed of adenosine, vasodilators, and heparin) were used in all RA patients, aiming to mitigate the impact of microthrombi and spasms.</p><p>The increased CMD observed following IVL was hypothesized to be primarily attributed to unavoidable atheromatous plaque debris, microvascular spasm, and embolization associated with the intervention (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>). Nonetheless, this phenomenon may be reversible, warranting further investigation. Additionally, a greater volume of debris generated during the intervention is associated with more severe coronary microvascular dysfunction (<xref rid="B37" ref-type="bibr">37</xref>). RA in narrower and longer vascular lesions may cause an excessive amount of debris, potentially leading to system obstruction, myocardial injury, and subsequent distal microvascular dysfunction (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B35" ref-type="bibr">35</xref>). However, the unfavorable crossing profile of the IVL balloon remains a limitation. In contrast, RA can achieve superior acute luminal gain to easier cross in cases of very severe and balloon-uncrossable lesions, resulting in increased AMR (<xref rid="B38" ref-type="bibr">38</xref>). Generally, RA is mainly used for more severe and complex calcified lesions, which could explain the higher AMR and incidence of procedure-related MI in this group.</p><p>Notably, even after excluding patients with procedure-related MI&#x02014;a known confounding factor for CMD and AMR elevation&#x02014;the RA group still demonstrated significantly higher &#x00394;AMR (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) and post-AMR (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) compared to IVL, consistent with the overall cohort results. These findings suggest that the microvascular protection advantage of IVL is independent of procedure-related MI occurrence.</p><p>Although RA patients showed a higher incidence of peri-procedural adverse events (27.9% vs. 17.1%, <italic>p</italic>&#x02009;=&#x02009;0.088), including myocardial injury, procedure-related MI, and TIMI flow&#x02009;&#x0003c;&#x02009;3, the small numbers and retrospective nature of this study precluded definitive conclusions. Larger prospective studies are warranted to validate whether the numerical trend reflects inherent differences between the techniques or is influenced by lesion selection bias (RA being used for more complex cases). Still, such negative clinical outcomes are likely to improve with further development of the technique and better case selection, enabling IVL treatment for complex calcified coronary lesions.</p></sec><sec id="s5"><label>5</label><title>Limitations</title><p>The limitations of the present study should be acknowledged. First, the retrospective design inherently involves some bias, although measures such as propensity score matching and continuous enrollment were employed to minimize bias. Second, the potential confounding factors related to both patient and operator decisions could not be fully accounted for. Third, while the measurement of AMR was optimized using Murray's law and demonstrated high agreement with wire-based IMR, it remains less extensively validated than invasive physiological measurements. Fourth, adenosine was not routinely administered in this study to assess microcirculatory function, which limits our ability to differentiate between functional and structural coronary microvascular dysfunction. Finally, this study provided only a temporary assessment of microcirculatory function, and continuous monitoring was not conducted, which could offer more comprehensive insights into the dynamics of microvascular function. The role of AMR in optimizing the management and outcomes of microcirculatory dysfunction will be further studied in future research.</p></sec><sec sec-type="conclusions" id="s6"><label>6</label><title>Conclusion</title><p>In patients presenting with calcified coronary lesions necessitating PCI, IVL resulted in lower post-AMR values compared to RA. Both groups exhibited similar rates of CMD (27% vs. 33%) and low rates of PPAEs (17% vs. 28%). Nevertheless, these preliminary results should be approached as hypothesis-generating. Substantiation of these findings necessitates larger-scale studies incorporating invasive physiological assessment, intravascular imaging, and clinical follow-up.</p></sec></body><back><ack><title>Acknowledgments</title><p>We offer our sincerest gratitude to Zhongshan Hospital of Fudan University and Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College for their cooperation and support, as well as for their contributions to this study. We thank Home for Researchers editorial team (<ext-link xlink:href="http://www.home-for-researchers.com" ext-link-type="uri">http://www.home-for-researchers.com</ext-link>) for language editing service.</p></ack><fn-group><title>Abbreviations</title><fn fn-type="abbr" id="ab001"><p>RA, rotational atherectomy&#x0037e; IVL, intravascular Lithotripsy; AMR, angiography-derived microcirculatory resistance&#x0037e; PCI, percutaneous coronary intervention; IMR, index of microvascular resistance&#x0037e; CMD, coronary microvascular dysfunction; MACE, major adverse cardiovascular events. PPAEs, Peri-Procedural Adverse Events.</p></fn></fn-group><sec sec-type="data-availability" id="s7"><title>Data availability statement</title><p>The datasets presented in this article are not readily available because the data supporting the findings of this study are available from Yan'an Hospital of Kunming City, Zhongshan Hospital of Fudan University, and Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College. Restrictions apply to the availability of these data which are used under license for the current study and are not publicly available. Requests to access the datasets should be directed to XueQiang, <email>xueqiang3513@126.com</email>.</p></sec><sec sec-type="ethics-statement" id="s8"><title>Ethics statement</title><p>The studies involving humans were approved by the Ethics Committee of Yan'an Hospital of Kunming City (approval number: YAXLL-AF-SC-023/16). The studies were conducted in accordance with the local legislation and institutional requirements. The ethics committee/institutional review board waived the requirement of written informed consent for participation from the participants or the participants&#x02019; legal guardians/next of kin because Due to the retrospective data collection, informed consent was waived, given the institutional ethics regulations regarding the nature of this observational study.</p></sec><sec sec-type="author-contributions" id="s9"><title>Author contributions</title><p>XZ: Funding acquisition, Resources, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing, Formal analysis, Conceptualization, Data curation, Investigation, Methodology, Software, Validation, Visualization. PW: Data curation, Resources, Supervision, Writing &#x02013; review &#x00026; editing. CL: Writing &#x02013; review &#x00026; editing, Data curation, Resources, Supervision. TZ: Investigation, Software, Writing &#x02013; review &#x00026; editing. JH: Investigation, Software, Writing &#x02013; review &#x00026; editing. BL: Investigation, Software, Writing &#x02013; review &#x00026; editing. QJ: Investigation, Writing &#x02013; review &#x00026; editing, Methodology, Software. PG: Writing &#x02013; review &#x00026; editing, Investigation. JZ: Investigation, Writing &#x02013; review &#x00026; editing. QX: Writing &#x02013; review &#x00026; editing, Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing &#x02013; original draft.</p></sec><sec sec-type="COI-statement" id="s11"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s12"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s13"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>L</given-names></name><name><surname>Jaeger</surname><given-names>BC</given-names></name><name><surname>Scialla</surname><given-names>JJ</given-names></name><name><surname>Budoff</surname><given-names>MJ</given-names></name><name><surname>Mehta</surname><given-names>RC</given-names></name><name><surname>Jaar</surname><given-names>BG</given-names></name><etal/></person-group>
<article-title>Progression of coronary artery calcification and risk of clinical events in CKD: the chronic renal insufficiency cohort study</article-title>. <source>Am J Kidney Dis</source>. (<year>2024</year>) <volume>1</volume>:<fpage>67</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1053/j.ajkd.2024.06.018</pub-id><pub-id pub-id-type="pmid">39154888</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdel-Wahab</surname><given-names>M</given-names></name><name><surname>Richardt</surname><given-names>G</given-names></name><name><surname>Joachim B&#x000fc;ttner</surname><given-names>H</given-names></name><name><surname>Toelg</surname><given-names>R</given-names></name><name><surname>Geist</surname><given-names>V</given-names></name><name><surname>Meinertz</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>High-speed rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: the randomized ROTAXUS (rotational atherectomy prior to Taxus Stent treatment for complex native coronary artery disease) trial</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2013</year>) <volume>6</volume>:<fpage>10</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2012.07.017</pub-id><pub-id pub-id-type="pmid">23266232</pub-id>
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>SK</given-names></name><name><surname>Bolduan</surname><given-names>RW</given-names></name><name><surname>Patel</surname><given-names>MR</given-names></name><name><surname>Martinsen</surname><given-names>BJ</given-names></name><name><surname>Azemi</surname><given-names>T</given-names></name><name><surname>Giugliano</surname><given-names>G</given-names></name><etal/></person-group>
<article-title>Impact of calcification on percutaneous coronary intervention: MACE-trial 1-year results</article-title>. <source>Catheter Cardiovasc Interv</source>. (<year>2019</year>) <volume>94</volume>:<fpage>187</fpage>&#x02013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1002/ccd.28099</pub-id><pub-id pub-id-type="pmid">30681262</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Waha</surname><given-names>S</given-names></name><name><surname>Allali</surname><given-names>A</given-names></name><name><surname>B&#x000fc;ttner</surname><given-names>HJ</given-names></name><name><surname>Toelg</surname><given-names>R</given-names></name><name><surname>Geist</surname><given-names>V</given-names></name><name><surname>Neumann</surname><given-names>FJ</given-names></name><etal/></person-group>
<article-title>Rotational atherectomy before paclitaxel-eluting stent implantation in complex calcified coronary lesions: two-year clinical outcome of the randomized ROTAXUS trial</article-title>. <source>Catheter Cardiovasc Interv</source>. (<year>2016</year>) <volume>87</volume>:<fpage>691</fpage>&#x02013;<lpage>700</lpage>. <pub-id pub-id-type="doi">10.1002/ccd.26290</pub-id><pub-id pub-id-type="pmid">26525804</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tomey</surname><given-names>MI</given-names></name><name><surname>Kini</surname><given-names>AS</given-names></name><name><surname>Sharma</surname><given-names>SK</given-names></name></person-group>. <article-title>Current status of rotational atherectomy</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2014</year>) <volume>7</volume>:<fpage>345</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2013.12.196</pub-id><pub-id pub-id-type="pmid">24630879</pub-id>
</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Florek</surname><given-names>K</given-names></name><name><surname>Bartoszewska</surname><given-names>E</given-names></name><name><surname>Biega&#x00142;a</surname><given-names>S</given-names></name><name><surname>Klimek</surname><given-names>O</given-names></name><name><surname>Malcharczyk</surname><given-names>B</given-names></name><name><surname>K&#x000fc;bler</surname><given-names>P</given-names></name></person-group>. <article-title>Rotational atherectomy, orbital atherectomy, and intravascular lithotripsy comparison for calcified coronary lesions</article-title>. <source>J Clin Med</source>. (<year>2023</year>) <volume>12</volume>:<fpage>7246</fpage>. <pub-id pub-id-type="doi">10.3390/jcm12237246</pub-id><pub-id pub-id-type="pmid">38068298</pub-id>
</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Maria</surname><given-names>GL</given-names></name><name><surname>Scarsini</surname><given-names>R</given-names></name><name><surname>Banning</surname><given-names>AP</given-names></name></person-group>. <article-title>Management of calcific coronary artery lesions: is it time to change our interventional therapeutic approach?</article-title>
<source>JACC Cardiovasc Interv</source>. (<year>2019</year>) <volume>12</volume>:<fpage>1465</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2019.03.038</pub-id><pub-id pub-id-type="pmid">31395217</pub-id>
</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>P</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Prognostic value of angiography-derived index of microcirculatory resistance in patients with coronary artery disease undergoing rotational atherectomy</article-title>. <source>Rev Cardiovasc Med</source>. (<year>2023</year>) <volume>24</volume>:<fpage>131</fpage>. <pub-id pub-id-type="doi">10.31083/j.rcm2405131</pub-id><pub-id pub-id-type="pmid">39076748</pub-id>
</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksoy</surname><given-names>A</given-names></name><name><surname>Salazar</surname><given-names>C</given-names></name><name><surname>Becher</surname><given-names>MU</given-names></name><name><surname>Tiyerili</surname><given-names>V</given-names></name><name><surname>Weber</surname><given-names>M</given-names></name><name><surname>Jansen</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Intravascular lithotripsy in calcified coronary lesions: a prospective, observational, multicenter registry</article-title>. <source>Circ Cardiovasc Interv</source>. (<year>2019</year>) <volume>12</volume>:<fpage>e008154</fpage>. <pub-id pub-id-type="doi">10.1161/circinterventions.119.008154</pub-id><pub-id pub-id-type="pmid">31707803</pub-id>
</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>JM</given-names></name><name><surname>Kereiakes</surname><given-names>DJ</given-names></name><name><surname>Shlofmitz</surname><given-names>RA</given-names></name><name><surname>Klein</surname><given-names>AJ</given-names></name><name><surname>Riley</surname><given-names>RF</given-names></name><name><surname>Price</surname><given-names>MJ</given-names></name><etal/></person-group>
<article-title>Intravascular lithotripsy for treatment of severely calcified coronary artery disease</article-title>. <source>J Am Coll Cardiol</source>. (<year>2020</year>) <volume>76</volume>:<fpage>2635</fpage>&#x02013;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2020.09.603</pub-id><pub-id pub-id-type="pmid">33069849</pub-id>
</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Shrivastava</surname><given-names>A</given-names></name><name><surname>Dugal</surname><given-names>JS</given-names></name><name><surname>Chhikara</surname><given-names>S</given-names></name><name><surname>Vijayvergiya</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><etal/></person-group>
<article-title>Coronary intravascular lithotripsy in contemporary practice: challenges and opportunities in coronary intervention</article-title>. <source>Ther Adv Cardiovasc Dis</source>. (<year>2024</year>) <volume>18</volume>:<fpage>17539447241263444</fpage>. <pub-id pub-id-type="doi">10.1177/17539447241263444</pub-id><pub-id pub-id-type="pmid">39049591</pub-id>
</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A</given-names></name><name><surname>Shrivastava</surname><given-names>A</given-names></name><name><surname>Chhikara</surname><given-names>S</given-names></name><name><surname>Revaiah</surname><given-names>PC</given-names></name><name><surname>Mamas</surname><given-names>MA</given-names></name><name><surname>Vijayvergiya</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>Safety, efficacy, and optical coherence tomography insights into intravascular lithotripsy for the modification of non-eruptive calcified nodules: a prospective observational study</article-title>. <source>Catheter Cardiovasc Interv</source>. (<year>2024</year>) <volume>104</volume>:<fpage>688</fpage>&#x02013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1002/ccd.31217</pub-id><pub-id pub-id-type="pmid">39224005</pub-id>
</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Ji</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>Impact of plaque characteristics on percutaneous coronary intervention-related microvascular dysfunction: insights from angiographic microvascular resistance and intravascular ultrasound</article-title>. <source>Quant Imaging Med Surg</source>. (<year>2023</year>) <volume>13</volume>:<fpage>6037</fpage>&#x02013;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.21037/qims-23-414</pub-id><pub-id pub-id-type="pmid">37711841</pub-id>
</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aarnoudse</surname><given-names>W</given-names></name><name><surname>Fearon</surname><given-names>WF</given-names></name><name><surname>Manoharan</surname><given-names>G</given-names></name><name><surname>Geven</surname><given-names>M</given-names></name><name><surname>van de Vosse</surname><given-names>F</given-names></name><name><surname>Rutten</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Epicardial stenosis severity does not affect minimal microcirculatory resistance</article-title>. <source>Circulation</source>. (<year>2004</year>) <volume>110</volume>:<fpage>2137</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1161/01.Cir.0000143893.18451.0e</pub-id><pub-id pub-id-type="pmid">15466646</pub-id>
</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>MK</given-names></name><name><surname>Yeung</surname><given-names>AC</given-names></name><name><surname>Fearon</surname><given-names>WF</given-names></name></person-group>. <article-title>Invasive assessment of the coronary microcirculation: superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve</article-title>. <source>Circulation</source>. (<year>2006</year>) <volume>113</volume>:<fpage>2054</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1161/circulationaha.105.603522</pub-id><pub-id pub-id-type="pmid">16636168</pub-id>
</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahendiran</surname><given-names>T</given-names></name><name><surname>Bertolone</surname><given-names>D</given-names></name><name><surname>Viscusi</surname><given-names>MM</given-names></name><name><surname>Gallinoro</surname><given-names>E</given-names></name><name><surname>Keulards</surname><given-names>DCJ</given-names></name><name><surname>Collet</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>The influence of epicardial resistance on microvascular resistance reserve</article-title>. <source>J Am Coll Cardiol</source>. (<year>2024</year>) <volume>84</volume>:<fpage>512</fpage>&#x02013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2024.05.004</pub-id><pub-id pub-id-type="pmid">38754704</pub-id>
</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murai</surname><given-names>T</given-names></name><name><surname>Yonetsu</surname><given-names>T</given-names></name><name><surname>Kanaji</surname><given-names>Y</given-names></name><name><surname>Usui</surname><given-names>E</given-names></name><name><surname>Hoshino</surname><given-names>M</given-names></name><name><surname>Hada</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Prognostic value of the index of microcirculatory resistance after percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome</article-title>. <source>Catheter Cardiovasc Interv</source>. (<year>2018</year>) <volume>92</volume>:<fpage>1063</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1002/ccd.27529</pub-id><pub-id pub-id-type="pmid">29446567</pub-id>
</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishi</surname><given-names>T</given-names></name><name><surname>Murai</surname><given-names>T</given-names></name><name><surname>Ciccarelli</surname><given-names>G</given-names></name><name><surname>Shah</surname><given-names>SV</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Derimay</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Prognostic value of coronary microvascular function measured immediately after percutaneous coronary intervention in stable coronary artery disease: an international multicenter study</article-title>. <source>Circ Cardiovasc Interv</source>. (<year>2019</year>) <volume>12</volume>:<fpage>e007889</fpage>. <pub-id pub-id-type="doi">10.1161/circinterventions.119.007889</pub-id><pub-id pub-id-type="pmid">31525096</pub-id>
</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Jung</surname><given-names>JH</given-names></name><name><surname>Hwang</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Na</surname><given-names>SH</given-names></name><etal/></person-group>
<article-title>Coronary flow reserve and microcirculatory resistance in patients with intermediate coronary stenosis</article-title>. <source>J Am Coll Cardiol</source>. (<year>2016</year>) <volume>67</volume>:<fpage>1158</fpage>&#x02013;<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1016/j.jacc.2015.12.053</pub-id><pub-id pub-id-type="pmid">26965536</pub-id>
</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ai</surname><given-names>H</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>HP</given-names></name><etal/></person-group>
<article-title>Coronary angiography-derived index of microvascular resistance</article-title>. <source>Front Physiol</source>. (<year>2020</year>) <volume>11</volume>:<fpage>605356</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2020.605356</pub-id><pub-id pub-id-type="pmid">33391020</pub-id>
</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>KH</given-names></name><name><surname>Dai</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><etal/></person-group>
<article-title>Functional coronary angiography-derived index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2021</year>) <volume>14</volume>:<fpage>1670</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2021.05.027</pub-id><pub-id pub-id-type="pmid">34353599</pub-id>
</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qian</surname><given-names>G</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Deng</surname><given-names>D</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Qu</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Prognostic value of angiographic microvascular resistance in patients with ST-segment elevation myocardial infarction</article-title>. <source>Clinics (Sao Paulo)</source>. (<year>2024</year>) <volume>79</volume>:<fpage>100429</fpage>. <pub-id pub-id-type="doi">10.1016/j.clinsp.2024.100429</pub-id><pub-id pub-id-type="pmid">39053030</pub-id>
</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>GN</given-names></name><name><surname>Bates</surname><given-names>ER</given-names></name><name><surname>Bittl</surname><given-names>JA</given-names></name><name><surname>Brindis</surname><given-names>RG</given-names></name><name><surname>Fihn</surname><given-names>SD</given-names></name><name><surname>Fleisher</surname><given-names>LA</given-names></name><etal/></person-group>
<article-title>2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery</article-title>. <source>Circulation</source>. (<year>2016</year>) <volume>134</volume>:<fpage>e123</fpage>&#x02013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1161/cir.0000000000000404</pub-id><pub-id pub-id-type="pmid">27026020</pub-id>
</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valgimigli</surname><given-names>M</given-names></name><name><surname>Bueno</surname><given-names>H</given-names></name><name><surname>Byrne</surname><given-names>RA</given-names></name><name><surname>Collet</surname><given-names>JP</given-names></name><name><surname>Costa</surname><given-names>F</given-names></name><name><surname>Jeppsson</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS</article-title>. <source>Eur J Cardiothorac Surg</source>. (<year>2018</year>) <volume>53</volume>:<fpage>34</fpage>&#x02013;<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1093/ejcts/ezx334</pub-id><pub-id pub-id-type="pmid">29045581</pub-id>
</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>Jaffe</surname><given-names>AS</given-names></name><name><surname>Chaitman</surname><given-names>BR</given-names></name><name><surname>Bax</surname><given-names>JJ</given-names></name><name><surname>Morrow</surname><given-names>DA</given-names></name><etal/></person-group>
<article-title>[Fourth universal definition of myocardial infarction (2018)]</article-title>. <source>Kardiol Pol</source>. (<year>2018</year>) <volume>76</volume>:<fpage>1383</fpage>&#x02013;<lpage>415</lpage>. <pub-id pub-id-type="doi">10.5603/kp.2018.0203</pub-id><pub-id pub-id-type="pmid">30338834</pub-id>
</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>S</given-names></name><name><surname>Echavarria-Pinto</surname><given-names>M</given-names></name><name><surname>von Birgelen</surname><given-names>C</given-names></name><name><surname>Holm</surname><given-names>NR</given-names></name><name><surname>Pyxaras</surname><given-names>SA</given-names></name><name><surname>Kumsars</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Fractional flow reserve and coronary bifurcation anatomy: a novel quantitative model to assess and report the stenosis severity of bifurcation lesions</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2015</year>) <volume>8</volume>:<fpage>564</fpage>&#x02013;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2014.12.232</pub-id><pub-id pub-id-type="pmid">25819180</pub-id>
</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mejia-Renteria</surname><given-names>H</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Choi</surname><given-names>KH</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Kakuta</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Coronary microcirculation assessment using functional angiography: development of a wire-free method applicable to conventional coronary angiograms</article-title>. <source>Catheter Cardiovasc Interv</source>. (<year>2021</year>) <volume>98</volume>:<fpage>1027</fpage>&#x02013;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1002/ccd.29863</pub-id><pub-id pub-id-type="pmid">34242489</pub-id>
</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>K</given-names></name><name><surname>Lovatt</surname><given-names>S</given-names></name><name><surname>Borovac</surname><given-names>JA</given-names></name><name><surname>Parasuraman</surname><given-names>S</given-names></name><name><surname>Kwok</surname><given-names>CS</given-names></name></person-group>. <article-title>Planned versus bailout rotational atherectomy: a systematic review and meta-analysis</article-title>. <source>Cardiovasc Revasc Med</source>. (<year>2022</year>) <volume>39</volume>:<fpage>45</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/j.carrev.2021.09.013</pub-id><pub-id pub-id-type="pmid">34627732</pub-id>
</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>ZA</given-names></name><name><surname>Brinton</surname><given-names>TJ</given-names></name><name><surname>Hill</surname><given-names>JM</given-names></name><name><surname>Maehara</surname><given-names>A</given-names></name><name><surname>Matsumura</surname><given-names>M</given-names></name><name><surname>Karimi Galougahi</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Optical coherence tomography characterization of coronary lithoplasty for treatment of calcified lesions: first description</article-title>. <source>JACC Cardiovasc Imaging</source>. (<year>2017</year>) <volume>10</volume>:<fpage>897</fpage>&#x02013;<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcmg.2017.05.012</pub-id><pub-id pub-id-type="pmid">28797412</pub-id>
</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Fezzi</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Ding</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><etal/></person-group>
<article-title><italic>In vivo</italic> validation of a novel computational approach to assess microcirculatory resistance based on a single angiographic view</article-title>. <source>J Pers Med</source>. (<year>2022</year>) <volume>12</volume>:<fpage>1798</fpage>. <pub-id pub-id-type="doi">10.3390/jpm12111798</pub-id><pub-id pub-id-type="pmid">36573725</pub-id>
</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>R</given-names></name><name><surname>Lan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name></person-group>. <article-title>Angiographic microvascular resistance in patients with obstructive hypertrophic cardiomyopathy</article-title>. <source>Microvasc Res</source>. (<year>2024</year>) <volume>153</volume>:<fpage>104656</fpage>. <pub-id pub-id-type="doi">10.1016/j.mvr.2024.104656</pub-id><pub-id pub-id-type="pmid">38278289</pub-id>
</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farhat</surname><given-names>H</given-names></name><name><surname>Kuzemczak</surname><given-names>M</given-names></name><name><surname>Durel</surname><given-names>N</given-names></name><name><surname>Caillot</surname><given-names>N</given-names></name><name><surname>Paw&#x00142;owski</surname><given-names>T</given-names></name><name><surname>Lipiecki</surname><given-names>J</given-names></name></person-group>. <article-title>Rotational atherectomy versus intravascular lithotripsy for calcified in-stent restenosis: a single-center study with 1-year follow-up</article-title>. <source>Am J Cardiol</source>. (<year>2023</year>) <volume>205</volume>:<fpage>413</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2023.07.174</pub-id><pub-id pub-id-type="pmid">37659262</pub-id>
</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>DD</given-names></name><name><surname>Auth</surname><given-names>DC</given-names></name><name><surname>Vracko</surname><given-names>R</given-names></name><name><surname>Ritchie</surname><given-names>JL</given-names></name></person-group>. <article-title>Rotational atherectomy in atherosclerotic rabbit iliac arteries</article-title>. <source>Am Heart J</source>. (<year>1988</year>) <volume>115</volume>:<fpage>160</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/0002-8703(88)90532-7</pub-id><pub-id pub-id-type="pmid">3336969</pub-id>
</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Belder</surname><given-names>AJ</given-names></name></person-group>. <article-title>Rotational atherectomy: re-emergence of an old technique</article-title>. <source>Heart</source>. (<year>2018</year>) <volume>104</volume>:<fpage>440</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1136/heartjnl-2016-310319</pub-id><pub-id pub-id-type="pmid">28500242</pub-id>
</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>SK</given-names></name><name><surname>Dangas</surname><given-names>G</given-names></name><name><surname>Mehran</surname><given-names>R</given-names></name><name><surname>Duvvuri</surname><given-names>S</given-names></name><name><surname>Kini</surname><given-names>A</given-names></name><name><surname>Cocke</surname><given-names>TP</given-names></name><etal/></person-group>
<article-title>Risk factors for the development of slow flow during rotational coronary atherectomy</article-title>. <source>Am J Cardiol</source>. (<year>1997</year>) <volume>80</volume>:<fpage>219</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/s0002-9149(97)00325-1</pub-id><pub-id pub-id-type="pmid">9230167</pub-id>
</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>J</given-names></name><name><surname>Kaski</surname><given-names>JC</given-names></name><name><surname>Lerman</surname><given-names>A</given-names></name></person-group>. <article-title>Coronary microvascular dysfunction in the clinical setting: from mystery to reality</article-title>. <source>Eur Heart J</source>. (<year>2012</year>) <volume>33</volume>:<fpage>2771</fpage>&#x02013;<lpage>2782b</lpage>. <pub-id pub-id-type="doi">10.1093/eurheartj/ehs246</pub-id><pub-id pub-id-type="pmid">22915165</pub-id>
</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsubokawa</surname><given-names>A</given-names></name><name><surname>Ueda</surname><given-names>K</given-names></name><name><surname>Sakamoto</surname><given-names>H</given-names></name><name><surname>Iwase</surname><given-names>T</given-names></name><name><surname>Tamaki</surname><given-names>S</given-names></name></person-group>. <article-title>Effect of intracoronary nicorandil administration on preventing no-reflow/slow flow phenomenon during rotational atherectomy</article-title>. <source>Circ J</source>. (<year>2002</year>) <volume>66</volume>:<fpage>1119</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1253/circj.66.1119</pub-id><pub-id pub-id-type="pmid">12499617</pub-id>
</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blachutzik</surname><given-names>F</given-names></name><name><surname>Meier</surname><given-names>S</given-names></name><name><surname>Weissner</surname><given-names>M</given-names></name><name><surname>Schlattner</surname><given-names>S</given-names></name><name><surname>Gori</surname><given-names>T</given-names></name><name><surname>Ullrich-Daub</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>Comparison of coronary intravascular lithotripsy and rotational atherectomy in the modification of severely calcified stenoses</article-title>. <source>Am J Cardiol</source>. (<year>2023</year>) <volume>197</volume>:<fpage>93</fpage>&#x02013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.amjcard.2023.02.028</pub-id><pub-id pub-id-type="pmid">37012181</pub-id>
</mixed-citation></ref></ref-list></back></article>